Precision BioSciences IncNASDAQ:DTIL
- LAST PRICE1.1800
- TODAY'S CHANGE (%)0.0200 (1.7241%)
- Bid / Lots1.1700/ 16
- Ask / Lots1.1800/ 6
- Open / Previous Close1.1500 / 1.1600
- Day Range
- 52 Week Range
- Volume180,438
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | DTIL |
|---|---|---|
| 09:32 ET | 2134 | 1.16 |
| 09:33 ET | 470 | 1.18 |
| 09:42 ET | 2137 | 1.19 |
| 09:44 ET | 2244 | 1.195 |
| 09:46 ET | 3200 | 1.1954 |
| 09:48 ET | 720 | 1.195 |
| 09:50 ET | 250 | 1.1934 |
| 09:51 ET | 3200 | 1.19 |
| 09:53 ET | 100 | 1.19 |
| 09:55 ET | 1100 | 1.19 |
| 09:57 ET | 400 | 1.19 |
| 10:00 ET | 4693 | 1.185 |
| 10:02 ET | 150 | 1.19 |
| 10:04 ET | 2600 | 1.19 |
| 10:06 ET | 600 | 1.18 |
| 10:08 ET | 200 | 1.18 |
| 10:09 ET | 813 | 1.19 |
| 10:11 ET | 640 | 1.19 |
| 10:18 ET | 100 | 1.2 |
| 10:20 ET | 7000 | 1.18 |
| 10:22 ET | 200 | 1.2 |
| 10:27 ET | 1190 | 1.18 |
| 10:31 ET | 100 | 1.2 |
| 10:33 ET | 3700 | 1.18 |
| 10:38 ET | 500 | 1.18 |
| 10:40 ET | 100 | 1.18 |
| 10:42 ET | 2132 | 1.183 |
| 10:44 ET | 3044 | 1.185 |
| 10:45 ET | 1000 | 1.175 |
| 10:47 ET | 1000 | 1.1733 |
| 10:49 ET | 230 | 1.17 |
| 10:56 ET | 200 | 1.17 |
| 10:58 ET | 999 | 1.17 |
| 11:00 ET | 3339 | 1.165 |
| 11:02 ET | 300 | 1.165 |
| 11:03 ET | 9824 | 1.165 |
| 11:05 ET | 100 | 1.165 |
| 11:07 ET | 2147 | 1.165 |
| 11:09 ET | 7407 | 1.165 |
| 11:12 ET | 300 | 1.16 |
| 11:14 ET | 700 | 1.155 |
| 11:16 ET | 1600 | 1.155 |
| 11:18 ET | 200 | 1.15 |
| 11:20 ET | 100 | 1.155 |
| 11:23 ET | 3300 | 1.155 |
| 11:25 ET | 300 | 1.155 |
| 11:27 ET | 500 | 1.155 |
| 11:30 ET | 100 | 1.155 |
| 11:32 ET | 5038 | 1.155 |
| 11:34 ET | 568 | 1.15 |
| 11:36 ET | 600 | 1.15 |
| 11:38 ET | 100 | 1.155 |
| 11:39 ET | 1120 | 1.155 |
| 11:41 ET | 100 | 1.155 |
| 11:45 ET | 20786 | 1.165 |
| 11:48 ET | 500 | 1.165 |
| 11:50 ET | 100 | 1.165 |
| 11:54 ET | 300 | 1.16 |
| 11:56 ET | 200 | 1.1621 |
| 11:57 ET | 23765 | 1.17 |
| 11:59 ET | 332 | 1.165 |
| 12:01 ET | 694 | 1.165 |
| 12:03 ET | 600 | 1.17 |
| 12:06 ET | 660 | 1.165 |
| 12:08 ET | 200 | 1.165 |
| 12:12 ET | 8457 | 1.17 |
| 12:14 ET | 1350 | 1.165 |
| 12:15 ET | 7256 | 1.17 |
| 12:17 ET | 200 | 1.165 |
| 12:19 ET | 100 | 1.165 |
| 12:21 ET | 225 | 1.1601 |
| 12:24 ET | 400 | 1.165 |
| 12:26 ET | 300 | 1.165 |
| 12:30 ET | 300 | 1.165 |
| 12:32 ET | 100 | 1.17 |
| 12:33 ET | 100 | 1.165 |
| 12:37 ET | 5839 | 1.17 |
| 12:39 ET | 1456 | 1.165 |
| 12:42 ET | 4313 | 1.165 |
| 12:44 ET | 300 | 1.17 |
| 12:46 ET | 952 | 1.165 |
| 12:48 ET | 2206 | 1.17 |
| 12:50 ET | 780 | 1.17 |
| 12:51 ET | 1077 | 1.175 |
| 12:53 ET | 1000 | 1.175 |
| 12:55 ET | 200 | 1.175 |
| 12:57 ET | 100 | 1.175 |
| 01:00 ET | 100 | 1.18 |
Jan 9, 2023
Precision BioSciences Recaps 2022 Accomplishments and Outlines 2023 Corporate Priorities and Planned Portfolio Milestones, from 7:30AM ET on Monday Jan 09, 2023 by Business Wire
7:30AM ET on Monday Jan 09, 2023 by Business Wire
Jan 6, 2023
Precision BioSciences Says it Received 'Favorable' US FDA Feedback on Azercabtagene Zapreleucel Development, from 10:14AM ET on Friday Jan 06, 2023 by MT Newswires
10:14AM ET on Friday Jan 06, 2023 by MT NewswiresBRIEF-Precision Biosciences Receives Favorable Type C Feedback From FDA, from 7:15AM ET on Friday Jan 06, 2023 by Thomson Reuters
7:15AM ET on Friday Jan 06, 2023 by Thomson ReutersPrecision BioSciences Receives Favorable Type C Feedback from the FDA on the Company's Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, its Lead Allogeneic CAR T Clinical Candidate, from 7:00AM ET on Friday Jan 06, 2023 by Business Wire
7:00AM ET on Friday Jan 06, 2023 by Business Wire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Precision BioSciences Inc | 128.7M | -0.8x | --- |
Athenex Inc | 29.3M | -0.1x | --- |
Kamada Ltd | 205.7M | -18.3x | --- |
Personalis Inc | 103.4M | -1.0x | --- |
Genfit SA | 203.5M | 6.0x | --- |
Acorda Therapeutics Inc | 23.2M | -0.1x | --- |
Company Information
Precision BioSciences, Inc. is a clinical stage gene editing company. It is developing ex vivo allogeneic CAR T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its owned ARCUS genome editing platform. The Company's ARCUS platform is designed to deliver therapeutic-grade genome editing. Its ARCUS genome editing technology is for deoxyribonucleic acid (DNA) genome insertion, deletion and repair. Its ARCUS is based on a naturally occurring genome editing enzyme, I-CreI, that evolved in the algae Chlamydomonas reinhardtii to make specific cuts and DNA insertions in cellular DNA. Its Ex vivo Allogeneic CAR T Immunotherapy pipeline offers programs, including PBCAR0191, PBCAR19B, PBCAR269A and CD19 Combination with Foralumab. Its in-vivo Gene Correction pipeline offers three preclinical programs, including PBGENE-PCSK9, PBGENE-PH1 and PBGENE-HBV. Its subsidiaries include Precision PlantSciences, Inc. and Precision BioSciences UK Limited.
Contact Information
- Headquarters
- 302 E Pettigrew St Ste A100DURHAM, NC, United States 27701-2393
- Phone
- 919-314-5512
- Fax
- 480-393-5553
Executives
- Lead Independent Chairman of the Board
- Kevin Buehler
- President, Chief Executive Officer, Director
- Michael Amoroso
- Chief Financial Officer
- Alex Kelly
- Chief People Officer
- Juli Blanche
- Chief Scientific Officer, Director
- Derek Jantz
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $128.7M |
|---|---|
Revenue (TTM) | $20.8M |
Shares Outstanding | 111.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.46 |
EPS | $-1.50 |
Book Value | $1.50 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | 6.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -502.15% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
